Glenmark Life Sciences Ltd.
Snapshot View

386.60 -3.35 ▼-0.9%

27 January 2023, 04:01:00 PM
Volume: 10,899

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarklifesciences.com
Market Cap 4,784.07 Cr.
Enterprise Value(EV) 4,372.34 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 34.24 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 11.40 Trailing Twelve Months Ending 2022-12
Industry PE 32.90 Trailing Twelve Months Ending 2022-12
Book Value / Share 183.44 Trailing Twelve Months Ending 2022-12
Price to Book Value 2.13 Calculated using Price: 390.45
Dividend Yield 5.38 Period Ending 2022-03
No. of Shares Subscribed 12.25 Cr. 122,527,172 Shares
FaceValue 2
Company Profile
The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.86%
1 Week
-3.54%
1 Month
-6.72%
3 Month
-6.76%
6 Month
-18.71%
1 Year
-31.71%
2 Year
5 Year
10 Year
5 years 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 451.05 127.84 60.91 29.87
Return on Capital Employed (%) 527.74 185.60 96.75 42.24
Return on Assets (%) -510.59 26.51 19.56 17.82 16.57

Balance Sheet View Details >>

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds -1 88 402 753 2,054 2,143
Non Curr. Liab. 7 16 23 33 42
Curr. Liab. 1 1,380 1,307 1,445 747 497
Minority Int.
Equity & Liab. 0 1,475 1,726 2,221 2,834 2,681
Non Curr. Assets 545 565 598 706 797
Curr. Assets 0 931 1,160 1,623 2,127 1,885
Misc. Exp. not W/O
Total Assets 0 1,475 1,726 2,221 2,834 2,681

Profit Loss View Details >>

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 0 886 1,537 1,885 2,123 2,054
Other Income 1 12 1 15 31
Total Income 0 887 1,549 1,886 2,138 2,085
Total Expenditure 0 -639 -1,065 -1,294 -1,507 -1,476
PBIDT 0 248 484 592 631 609
Interest -1 -34 -88 -28 -1
Depreciation -19 -29 -33 -38 -40
Taxation 0 -33 -108 -119 -146 -149
Exceptional Items
PAT 0 196 313 352 419 420
Adjusted EPS -8 18 29 33 34 34

Cash Flow View Details >>

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 10 195 388 598
Cash Fr. Inv. -9 -51 -69 -122
Cash Fr. Finan. 0 1 -137 -214 -79
Net Change 0 2 8 106 397
Cash & Cash Eqvt 0 2 10 116 512

Shareholding Pattern View Details >>

6 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 82.84 82.85 82.85 82.85 82.85 82.85
Public 17.16 17.15 17.15 17.15 17.15 17.15
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 28 Jan 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of Q3 FY2022-23 Earnings Call
Fri, 27 Jan 2023
Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2022
Pursuant to Regulations 30 and 33 of the SEBI LODR 2015 we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2022.The said meeting of the Board commenced at 11.00 a.m. and concluded at 12.30 p.m. The copy of the said results together with Management Discussion & Analysis Press Release and Limited Review Report of the Auditors is enclosed herewith.These are also being made available on the website of the Company at www.glenmarklifesciences.comYou are requested to take the same on record.
Fri, 27 Jan 2023
Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2022<BR> <BR>
Pursuant to Regulations 30 and 33 of the SEBI LODR 2015 we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2022.

The said meeting of the Board commenced at 11.00 a.m. and concluded at 12.30 p.m.

The copy of the said results together with Management Discussion & Analysis Press Release and Limited Review Report of the Auditors is enclosed herewith.

These are also being made available on the website of the Company at www.glenmarklifesciences.com

You are requested to take the same on record.

Technical Scans View Details >>

Fri, 27 Jan 2023
Higher Trade Quantity Higher Trade Quantity
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Week Low Close Below Last Week Low
Close Below Last Month Low Close Below Last Month Low

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Glenmark Life Sciences Ltd.

What is Glenmark Life Scienc share price?

Can I buy Glenmark Life Scienc shares now?

What is the Dividend Yield of Glenmark Life Scienc?

What is the Market Cap of Glenmark Life Scienc?

What are the key metrics to analyse Glenmark Life Scienc?

What is the 52 Week High and Low of Glenmark Life Scienc?

What is the trend of Glenmark Life Scienc share price?